drugset / Trial / NCT00582790
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is being done to see if we can improve the response of Interleukin-2 by adding Zoledronic acid. The effectiveness of the combination of drugs in kidney cancer is unknown and will be investigated in this study. In particular, this study will evaluate the effect of this combination on kidney cancer and will also examine the safety and side effects of IL-2 with Zoledronic acid.
Timeline
- Start
- 2003-08
- Primary completion
- 2008-08
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 400 ug | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 7 unknown | Subcutaneous |